in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance..

why novartis� landmark cancer drug approval is great news for bluebird..

the state launched a review into the newspaper�s findings in late april.